Nanjing Synnocare Pharmaceutical Technology Co. Ltd. and Tianjin Synnocare Biomedical Technology Co. Ltd. have jointly developed new N-myristoyltransferase 1 (NMT1) inhibitors reported to be useful for the treatment of cancer, malaria, leishmaniasis, rhinovirus and HIV infections.